Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P56159
UPID:
GFRA1_HUMAN
Alternative names:
RET ligand 1; TGF-beta-related neurotrophic factor receptor 1
Alternative UPACC:
P56159; A8KA21; O15507; O43912
Background:
GDNF family receptor alpha-1, also known as RET ligand 1 or TGF-beta-related neurotrophic factor receptor 1, plays a pivotal role in kidney and urinary tract development. It functions as a receptor for GDNF, facilitating the GDNF-induced autophosphorylation and activation of the RET receptor. This process is crucial for the proper development and function of the renal system.
Therapeutic significance:
The protein is directly linked to Renal hypodysplasia/aplasia 4, a severe congenital anomaly characterized by bilateral renal agenesis. Understanding the role of GDNF family receptor alpha-1 in this condition could pave the way for innovative therapeutic strategies aimed at mitigating or potentially curing this fatal disease.